Correction to: Chrysophanol exerts a protective effect against Aβ25‑35‑induced Alzheimer's disease model through regulating the ROS/TXNIP/NLRP3 pathway
Related Experiment Video
Updated: Jul 5, 2025
06:23
Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
8.0K
Meng Zhang1, Zhi-Xian Ding1, Wei Huang1
1Department of Integrated Traditional Chinese and Western Medicine, Key Laboratory of Xin'an Medicine (Anhui University of Chinese Medicine), Ministry of Education, Anhui University of Chinese Medicine, Hefei, 230012, People's Republic of China.
Inflammopharmacology
|January 18, 2024
Abstract
No abstract available in PubMed .
Related Concept Videos
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:26Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490